<DOC>
	<DOCNO>NCT01807455</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety Restylane Vital Lidocaine acne scar treat</brief_summary>
	<brief_title>An Open , Non-comparative Study Efficacy Safety Treatment Acne Scars With Restylane Vital Lidocaine</brief_title>
	<detailed_description />
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Male female age 25 45 year . Caucasian Fitzpatrick skin type IIII . Must cooperative willing comply instruction procedure . Provision sign date informed consent participate study . Presence depress facial atrophic acne scar diameter &lt; 4 mm accord least SCARS score 3 category moderate ( i.e . half face involve ) . Icepick scar atrophic scar diameter â‰¥4 mm cover 25 % face . Active acne inflammatory component . Postsurgical scar face . History keloid formation hypertrophic scar . Use isotretinoin within 12 month baseline visit . Use per oral topical ( facial ) substance contain retinoids , bensoyl peroxide , alphahydroxy acid concentration 10 % betahydroxy acid concentration 2 % antibiotic within four month baseline visit . Concomitant anticoagulant therapy therapy inhibitor platelet aggregation ( e.g . aspirin nonsteroidal antiinflammatory drug [ NSAIDs ] ) , Omega3 vitamin E seven day injection , history bleeding disorder . Use antiinflammatory agent seven day injection . History radiation skin tumour include actinic keratosis face . Active skin disease , inflammation related condition , infection , perioral dermatitis , seborrheic eczema rosacea face . History active collagen disease autoimmune disease systemic lupus erythematous , rheumatic arthritis , skin systemic sclerosis . Previous hypersensitivity HA . Previous hypersensitivity lidocaine amidetype anaesthetic . Concomitant treatment chemotherapy , immunosuppressive agent , immunomodulatory therapy ( e.g . monoclonal antibody ) , systemic topical ( facial ) corticosteroid within 3 month baseline visit . ( Inhaled corticoid exclusion criterion ) . Presence facial hair may interfere efficacy evaluation . Previous tissue augment therapy revitalization treatment treatment area HA collagen , within 12 month baseline visit . Permanent implant treatment filler base material HA collagen treatment area . Laser , e.g . carbon dioxide Fraxel , dermabrasion facial light therapy , e.g . IPL , treatment area within 12 month baseline visit . Chemical peel treatment area within 6 month baseline visit . Previous surgery treatment area . Nicotine use within 6 month baseline visit . Pregnancy breast feed . Participation clinical study within 30 day inclusion . Any medical condition opinion investigator make subject unsuitable inclusion ( e.g . severe chronic disease , epilepsy , impaired cardiac conduction , severely impaired hepatic function severe renal dysfunction ) . Other condition prevent subject enter study investigator 's opinion , e.g . subject likely avoid facial cosmetic treatment , subject anticipate unreliable incapable understanding study assessment unrealistic expectation treatment result . Study staff close relative study staff ( e.g . parent , child , sibling spouse ) .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>